The Swedish BioFINDER 2 Study

Recruiting N/A Interventional Study
Dementia Alzheimer Disease Parkinson Disease Lewy Body Disease Parkinson-Dementia Syndrome Frontotemporal Degeneration Semantic Dementia Progressive Nonfluent Aphasia Progressive Supranuclear Palsy Corticobasal Degeneration Multiple System Atrophy Mild Cognitive Impairment ALS (Amyotrophic Lateral Sclerosis)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
20 – 100
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
2,950 (estimated)
Sponsor
Skane University Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in cerebrospinal fluid samples. The BioFINDER 1 study has resulted in more than …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
COHORT A: Cognitively healthy younger individuals (40-65 years of age) INCLUSION CRITERIA * Age 40-65 years * Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders. * MMSE score 27-30 at screening visit. * Do not fulfill the criteria for MCI or any de…
Contacts

Erik Stomrud, MD, PhD

+46 40 33 10 00

erik.stomrud@med.lu.se

CONTACT

Sebastian Palmqvist, MD, PhD

+46 40 33 10 00

sebastian.palmqvist@med.lu.se

CONTACT